HER-2 Positive Locally Advanced Breast Cancer
Showing 1 - 25 of >10,000
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- Eribulin mesylate injection、Pertuzumab、Trastuzumab
-
Guanzhou, Guangdong, ChinaLI YuDong
Jul 13, 2023
Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)
Not yet recruiting
- Breast Neoplasms
- Disitamab Vedotin
- Toripalimab
-
Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
- +2 more
Oct 23, 2023
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)
Recruiting
- Metastatic Breast Cancer
- +2 more
-
Ocala, FloridaOcala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023
Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F
Not yet recruiting
- Breast Cancer
- Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
- Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
- (no location specified)
Feb 22, 2023
ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)
Recruiting
- ER+, HER2- Advanced Breast Cancer
- Metastatic Breast Cancer
- TFX06 tablet
-
Luoyang, Henan, China
- +1 more
Jun 25, 2023
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial
Not yet recruiting
- Hormone Receptor-positive Breast Cancer
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Oct 5, 2022
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a
Recruiting
- ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
- a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
- Durvalumab
- +2 more
-
Montpellier, France
- +1 more
Nov 16, 2022
Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (SPH4336 Tablets, SPH4336 Tablets Placebo)
Not yet recruiting
- Locally Advanced or Metastatic Breast Cancer
- SPH4336 Tablets
- SPH4336 Tablets Placebo
-
Guangzhou, Guangdong, ChinaAffiliated Cancer Hospital, Sun Yat-sen University
May 8, 2023
Human Epidermal Growth Factor Receptor 2-Positive Unresectable
Active, not recruiting
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
-
Athens, Greece
- +1 more
Jun 20, 2022
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)
Recruiting
- Locally Advanced Breast Cancer
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 11, 2022
Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)
Recruiting
- Breast Cancer
- Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
-
Chengdu, Chengdu, Sichuan, China, ChinaWest China Hospital, Sichuan University
Oct 7, 2022
Tucatinib in Locally Advanced or Metastatic HER2-positive Breast
Recruiting
- HER2-positive Breast Cancer
-
Essen, Northrhine-Westphalia, GermanyUniversitätsklinikum Essen, Innere Klinik (Tumorforschung)
May 30, 2022
Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)
Recruiting
- Locally Advanced Breast Cancer
- Chemotherapy Effect
- inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 28, 2023
HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)
Active, not recruiting
- HER2-positive Breast Cancer
- TQB2440 injection + Trastuzumab + Docetaxel
- Perjeta + Trastuzumab + Docetaxel
-
Chongqing, Chongqing, China
- +5 more
Aug 3, 2023
Locally Advanced or Metastatic Breast Cancer Trial in Guangzhou (SPH4336 Tablets 400mg, SPH4336 Tablets Placebo)
Not yet recruiting
- Locally Advanced or Metastatic Breast Cancer
- SPH4336 Tablets 400mg
- SPH4336 Tablets Placebo
-
Guangzhou, Guangdong, ChinaAffiliated Cancer Hospital, Sun Yat-sen University
Feb 24, 2023
Breast Cancer Trial (Intuzumab, pyrrolidone, nab-paclitaxel)
Not yet recruiting
- Breast Cancer
- Intuzumab, pyrrolidone, nab-paclitaxel
- (no location specified)
Jun 29, 2022
Breast Cancer, Locally Advanced or Metastatic Solid Tumor Trial in Guangdong (BL-M07D1)
Not yet recruiting
- Breast Cancer
- Locally Advanced or Metastatic Solid Tumor
-
Guangdong, Guangzhou, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2022
Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)
Recruiting
- Locally Advanced Breast Cancer
- Hormone Receptor Positive，HER2-negative Breast Cancer
-
Jinan, Shandong, ChinaBreast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023